Aberdeen Group plc Boosts Stock Position in Dyne Therapeutics, Inc. $DYN

Aberdeen Group plc boosted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 15.0% in the third quarter, HoldingsChannel.com reports. The firm owned 556,733 shares of the company’s stock after acquiring an additional 72,770 shares during the period. Aberdeen Group plc’s holdings in Dyne Therapeutics were worth $7,043,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. TCG Crossover Management LLC grew its holdings in shares of Dyne Therapeutics by 42.1% during the second quarter. TCG Crossover Management LLC now owns 3,766,660 shares of the company’s stock valued at $35,859,000 after buying an additional 1,116,510 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Dyne Therapeutics during the second quarter worth about $30,378,000. JPMorgan Chase & Co. boosted its position in Dyne Therapeutics by 21.9% in the second quarter. JPMorgan Chase & Co. now owns 3,086,779 shares of the company’s stock valued at $29,386,000 after buying an additional 555,466 shares during the last quarter. Geode Capital Management LLC increased its holdings in Dyne Therapeutics by 15.2% in the 2nd quarter. Geode Capital Management LLC now owns 2,253,670 shares of the company’s stock worth $21,458,000 after buying an additional 298,165 shares during the period. Finally, Frazier Life Sciences Management L.P. lifted its stake in Dyne Therapeutics by 4.3% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,505,984 shares of the company’s stock valued at $14,337,000 after acquiring an additional 62,643 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $14.88 on Friday. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $25.00. The business’s 50 day moving average is $17.92 and its two-hundred day moving average is $16.78. The company has a market capitalization of $2.13 billion, a P/E ratio of -4.07 and a beta of 1.30.

Analyst Ratings Changes

A number of analysts have recently weighed in on DYN shares. Robert W. Baird set a $30.00 price objective on shares of Dyne Therapeutics in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. JPMorgan Chase & Co. reduced their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Royal Bank Of Canada upped their target price on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $11.00 to $40.00 in a report on Wednesday, December 10th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.41.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.